Abstract:The clinical significance of the male factor in infertility has been well-recognized for years. Approximately 50% of the infertility in couples is considered to be caused at least to some degree by the male. Alarming findings of the globally decreasing semen quality have further highlighted the importance of andrology as a field of research as well as clinical specialty. The development of intracytoplasmic sperm injection (ICSI) in 1992 was for several years considered to largely solve the challenges of male infertility.[1] In retrospect, although completely new groups of infertile men could be treated effectively with this method, the research activity in andrology became focused less on improving male fertility as a result. Recent years have witnessed the elevated appreciation of the male factor. In addition to basic research advancing our understanding of spermatogenesis, the event of paramount importance in male fertility, new methods are being employed to further develop the diagnosis of male infertility as well as the treatment. This issue of Seminars in Reproductive Medicine is dedicated to andrology, a selection of seven reviews covering some of the highlights of the advances in this important specialty. Small non-coding RNAs (sncRNAs) regulate activities in both somatic and germ cells. miRNAs are well conserved among species and their expression is specific to different cell types, developmental stage, as well as disease type.[2] They are involved in multiple physiological events as well as different diseases.[3] On the other hand, PIWI-interacting RNAs (piRNAs) are predominantly expressed in the male germline. The article by professor Kotaja's group reviews the complex roles of the sncRNAs in spermatogenesis.[4] The animal models have shown that these sncRNAs play a critical role in male germ cell maturation, and abnormalities may lead to compromised male fertility. Even if currently most of the findings appear to be of largely basic science interest, the sncRNAs may well find clinical use as indicators and/or markers of male infertility, male reproductive disorders, and even assist in predicting the outcome of medically assisted reproduction. Multiple studies have displayed alarming findings suggesting deteriorating male fertility in the form of decreasing quality of semen.[5] The possible role of environmental factors in this alarming development is discussed in detail in the review by Toppari et al.[6] In addition to reviewing the endocrine disrupting chemicals, this seminar importantly discusses the sensitive developmental stages in individual male development (fetal, mini-puberty, and puberty), which may determine the spermatogenic capacity irrespective of exposures in adulthood. Several chemicals have been banned and the monitoring has been improved; however, more reliable research data are essential to ensure appropriate regulation and monitoring of a vast array of chemicals to ensure that the fertility of men and women as well as all other species is not irreversibly endangered. Sperm DNA fragmentation is clearly among the hottest topics in andrology at the moment. The association with poor fertility, risk of miscarriage, and lack of success in treatments with assisted reproductive techniques is apparent. When should DNA fragmentation be measured? How can it be effectively treated, and should it affect the infertility treatment choices? What do the different methods in evaluating DNA fragmentation actually test? Moller Nielsen et al review the available methods to measure sperm DNA fragmentation, how the results should be interpreted, and importantly what can be done to minimize the detrimental effect of fragmentation and how to avoid the negative consequences.[7] The possibility of transgenerational effects of this phenomenon is discussed. Nearly all infertility treatments targeting women are employing gonadotropins, follicle-stimulating hormone (FSH), as well as luteinizing hormone/human chorionic gonadotropin. However, the use of FSH in the treatment of male infertility has been far more limited and the doses used could be rather considered replacement than pharmacology in dosing. In their article, Romeo et al[8] review, in addition to summarizing the use of gonadotropins in IVF stimulation, the data supporting the use of FSH in treating male infertility. FSH has a clear role in the treatment of azoospermia in men with hypogonadotropic hypogonadism. However, the potential effect of improving semen quality with FSH in cases when no apparent etiology can be identified is far less obvious. The current knowledge as well as gaps in our knowledge on FSH treatment are covered in this Seminar . Nonobstructive azoospermia (NOA) is the most severe form of male infertility. Microscopic testicular sperm extraction (micro-TESE) has been proven to be the most effective method of retrieving sperm from the te -Abstract Truncated-

(350) Efficacy And Predictors Of Spermatogenesis Induction Upon Gonadotropin And Gnrh Therapy In Congenital Hypogonadotropic Hypogonadism: A Meta-Analysis

Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta‐Analysis

Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism

Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism

Pulsatile gonadotropin releasing hormone therapy for spermatogenesis in congenital hypogonadotropic hypogonadism patients who had poor response to combined gonadotropin therapy

Effect of Combined Low Dose Human Gonadotropic Hormone, Follicle Stimulating Hormone, and Testosterone Therapy (LFT Regimen) Versus Conventional High Dose Human Gonadotropic Hormone and Follicle Stimulating Hormone on Spermatogenesis and Biomarkers in Men With Hypogonadotropic Hypogonadism

Fertility outcomes in male adults with congenital hypogonadotropic hypogonadism treated during puberty with human chorionic gonadotropin and recombinant follicle stimulating hormone

Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism

[Effect and safety of pulsatile GnRH therapy for male congenital hypogonadotropic hypogonadism]

(253) Comparative Effectiveness in Testosterone Levels and Sperm Parameters of Medical Treatments for Primary Infertility and Testicular Deficiency

FSH Therapy in Male Factor Infertility: Evidence and Factors Which Might Predict the Response

Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism

(299) The Modulating Effects of Follicle Stimulating Hormone and Clomid on Men with Azoospermia or Oligozoospermia Taking Human Chorionic Gonadotropin

Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations

Correlations Among Genotype and Outcome in Chinese Male Patients With Congenital Hypogonadotropic Hypogonadism Under HCG Treatment

Two livebirths achieved in cases of hypergonadotropic hypogonadism nonobstructive azoospermia, treated with GnRH agonist and gonadotrophins: a case series and review of the literature

Eligibility for the medical therapy among men with non‐obstructive azoospermia—Findings from a multi‐centric cross‐sectional study

Male infertility: non-surgical therapy

Andrology: The Male Factor

Investigational Treatment of Congenital Hypogonadotropic Hypogonadism in Infants

Gonadotropin Releasing Hormone Agonist and Standard Dosage of Human Chorionic Gonadotropin Trigger Improve the in Vitro Fertilization and Embryo Transfer/intracytoplasmic Sperm Injection Treatment Prognosis of Patients with History of Poor Fertilization Outcomes